An Observational Study of the First Experience with Bevacizumab for the Treatment of Patients with Recurrent High-Grade Glioma in Two Belgian University Hospitals

Figure 1

Maximal % change in tumor surface area on gadolinium-enhanced T1-weighted MRI (Blue bar) and surface area of nonenhancing lesions on T2-weighted MRI (Red bar) as compared to baseline during BEV therapy. Patient no. 14 had a decrease of the measured contrast-enhancing lesion; however, a new contrast-enhancing lesion appeared in a different location.